Home/Cosmetic Surgery For Women/Cosmetic Surgery For Men/Plastic Surgery After Massive
Weight Loss/Thermage®/Botox®/Skin Care/Injectable Skin Fillers/The Office
Privacy/Contact Us/Sitemap
Ramin A. Behmand, M.D.
Plastic & Cosmetic Surgery
Return To Publications Page.

Return To Dr. Behmand Page.


1776 Ygnacio Valley Rd, Suite 108
Walnut Creek, California 94598
Tel: (925) 939-9200
1776 Ygnacio Valley Rd, Suite 108, Walnut Creek, California  94598
Telephone: (925) 939-9200  Facsimile: (925) 939-9205

Home/Cosmetic Surgery For Women/Cosmetic Surgery For Men/Plastic Surgery After Massive
Weight Loss/Thermage®/Botox®/Skin Care/Injectable Skin Fillers/The Office
Privacy/Contact Us/Sitemap
Single-Site Botulinum Toxin Type a Injection
For Elimination Of Migraine Trigger Points

Behmand RA, Tucker T, Guyuron B.

BACKGROUND: Botulinum toxin may be effective in suppressing
migraine. Most injection regimens utilized have involved multiple sites.
PURPOSE: To evaluate prospectively the effect of botulinum toxin type A
injections into the corrugator supercilii muscles alone on the frequency and
severity of migraine. METHODS: Twenty-nine patients (24 women, 5 men)
with migraine were enrolled in the study. Average age was 45 years (range,
24 to 63). The frequency (number of migraines per month) and intensity
(recorded on an analog scale of 1 to 10, 10 being most severe) of headache
were recorded before and after treatment. Twenty-five units of botulinum
toxin type A was injected into each corrugator supercilii muscle, for a total
of 50 units. RESULTS: At 2 months, 24 (83%) of 29 patients reported a
positive response to the injection of botulinum toxin type A (P <.001).
Sixteen patients (55%) reported complete elimination of headache (P
<.001), 8 (28%) experienced significant improvement (at least 50%
reduction in frequency or intensity) (P <.04), and 5 (17%) did not notice a
change in headache. The duration of efficacy of the botulinum toxin type A
injections ranged from 6 to 12 weeks, with an average of 8 weeks. In patients
who had improvement in migraine but not complete elimination, the
headache frequency decreased from 6.4 to 2.1 per month on average (P
<.04), and the intensity decreased from 8.6 to 6.1 (P <.04).
CONCLUSION: These results support the hypothesis that focal injection of
botulinum toxin type A may be an effective therapy for migraine.